Kwamena William Coleman Sagoe

<i>CYP2B6</i> (c.516G→T) and <i>CYP2A6</i> (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV‐infected patients

Awewura Kwara, Margaret Lartey, Kwamena William Coleman Sagoe et al. · British Journal of Clinical Pharmacology · 2009 · 116 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +10

Phenotyping Stroke in Sub-Saharan Africa: Stroke Investigative Research and Education Network (SIREN) Phenomics Protocol

Albert Akpalu, Fred Stephen Sarfo, Bruce Ovbiagele et al. · Neuroepidemiology · 2015 · 97 citations

Life Sciences, Bioinformatics, Neurology +17

HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study

Adwoa K. A. Afrane, Bamenla Q. Goka, Lorna Renner et al. · BMC Infectious Diseases · 2021 · 56 citations · Full text

Public Health, Infectious Diseases, Pediatrics +14

Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

Awewura Kwara, Margaret Lartey, Kwamena William Coleman Sagoe et al. · AIDS · 2010 · 54 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Pharmacokinetics of Efavirenz When Co‐administered With Rifampin in TB/HIV Co‐infected Patients: Pharmacogenetic Effect of<i>CYP2B6</i>Variation

Awewura Kwara, Margaret Lartey, Kwamena William Coleman Sagoe et al. · The Journal of Clinical Pharmacology · 2008 · 52 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +12